Cytek Biosciences, Inc.
NASDAQ:CTKBMedical - Devices
-$0.11 today
- Market cap
- $774.24M
- Beta
- 1.19
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$0.57
Volume 1.05M
Average 0.88M
CTKB Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Cytek Biosciences, Inc.NASDAQ: CTKB
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $2.81M fell 2.5% year over year, behind the +9.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 7.6% from the prior quarter. Over 3 fiscal years it compounded at +28.4% a year.
Context
- Depreciation & amortization amounted to 5.9% of revenue in FY2025, up 0.7 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -2.5% toward the trailing-twelve-month pace of +9.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 11.98M USD
- Year-over-year change
- +14.2%
- 4-year CAGR
- +76.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.98M | +14.2% |
| FY2024 | 2024-12-31 | 10.49M | +13.7% |
| FY2023 | 2023-12-31 | 9.23M | +63.1% |
| FY2022 | 2022-12-31 | 5.66M | +355.6% |
| FY2021 | 2021-12-31 | 1.24M | — |
Depreciation & Amortization vs competitors
How CTKB compares with its peers on the latest reported figures
- CTKB's LTM Mar 2026 depreciation & amortization of $11.9M is the 5th highest of the 6 companies compared; the peer median is $127.6M.
- Its year-over-year change of +9.1% is the 2nd highest of 6, against a peer median of -20.4%.
- Depreciation & amortization amounts to 5.8% of revenue for CTKB, versus a peer median of 5.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $271M | -5.2% | -3.1% | 3.7% | |
| LTM Jun 2026 | $230.1M | +9.4% | +35.4% | 6.6% | |
| LTM Jun 2026 | $127.6M | -23.5% | +6.4% | 4.9% | |
| LTM Sep 2026 | $33.67M | -20.4% | +9.9% | 5.4% | |
| LTM Mar 2026 | $11.9M | +9.1% | +28.4% | 5.8% | |
| LTM Mar 2026 | $6.29M | -60.3% | -22.5% | 7.3% | |
| Peer median (excluding CTKB) | $127.6M | -20.4% | +6.4% | 5.4% | |
Competitors are the stored peer set for CTKB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 127.95M | 164.04M | 193.02M | 200.45M | 201.49M |
| Cost of Revenue | 48.81M | 63.06M | 83.59M | 89.35M | 97.03M |
| Gross Profit | 79.14M | 100.97M | 109.43M | 111.11M | 104.46M |
| Gross Margin | 61.9% | 61.6% | 56.7% | 55.4% | 51.8% |
| Research & Development | 24.44M | 34.86M | 44.15M | 39.4M | 36.47M |
| Selling, General & Admin | 45.55M | 67.92M | 93.12M | 92.23M | 108.38M |
| Operating Expenses | 69.99M | 102.78M | 137.27M | 131.63M | 144.84M |
| Depreciation & Amortization | 1.24M | 5.66M | 9.23M | 10.49M | 11.98M |
| EBITDA | 8.92M | 9.49M | (4.41M) | 4.79M | (17.39M) |
| EBITDA Margin | 7.0% | 5.8% | -2.3% | 2.4% | -8.6% |
| Operating Income | 9.16M | (1.8M) | (27.85M) | (20.52M) | (40.38M) |
| Operating Margin | 7.2% | -1.1% | -14.4% | -10.2% | -20.0% |
| Interest Income | 49K | 4.62M | 6.41M | 10.36M | 2.22M |
| Interest Expense | 1.74M | 2.57M | 2.07M | 0 | 474K |
| Other Income / Expenses | (3.22M) | 3.06M | 12.14M | 14.82M | 10.54M |
| Income Before Tax | 5.94M | 1.26M | (15.71M) | (5.7M) | (29.84M) |
| Pre-Tax Margin | 4.6% | 0.8% | -8.1% | -2.8% | -14.8% |
| Income Tax Expense | 2.91M | (1.22M) | (3.56M) | 320K | 36.7M |
| Net Income | 3M | 2.58M | (12.15M) | (6.02M) | (66.54M) |
| Net Margin | 2.3% | 1.6% | -6.3% | -3.0% | -33.0% |
| EPS (Basic) | 0.03 | 0.02 | (0.09) | (0.05) | (0.52) |
| EPS (Diluted) | 0.03 | 0.02 | (0.09) | (0.05) | (0.52) |
| Weighted Avg Shares | 133.75M | 134.51M | 135.28M | 130.61M | 127.75M |
| Weighted Avg Shares (Diluted) | 133.75M | 138.56M | 135.28M | 130.61M | 127.75M |
Cytek Biosciences, Inc.
NASDAQ:CTKB
Intrinsic Alpha fair value
Locked
Current Price
$5.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.